# US 2006/0153920 A1 · Lyophilized pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153920 A1
- Document ID: US20060153920A1
- Status: Published application
- Kind: A1
- Application number: 11/312,862
- Filed: 2005-12-20
- Published: 2006-07-13
- Earliest claimed: 2004-09-24
- Inventors: Ketan Amin; Rose-Marie Dannenfelser; Joseph Zielinski; Barbara Wang
- Web page: https://patentgrep.com/patent/US20060153920A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Pharmaceutical compositions that include a poorly water-soluble therapeutic compound, an aqueous solvent, a nonvolatile cosolvent and a bulking agent. The pharmaceutical compositions can be orally ingested or administered parenterally. The pharmaceutical compositions can further be lyophilized to form a pharmaceutically acceptable cake that can be administered orally, e.g., as a solid oral dosage form; or reconstituted and administered parenterally, e.g. as a single i.v. bolus.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(a) a therapeutic compound;
(b) an aqueous solvent;
(c) a nonvolatile cosolvent; and
(d) a bulking agent.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said composition further comprises an aqueous solvent.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said nonvolatile cosolvent comprises thirty percent or less by weight per volume of the composition.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said bulking agent comprises five percent or less by weight per volume of the composition.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said therapeutic compound is poorly water-soluble.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said bulking agent is a solid polyethylene glycol (PEG).

### Claim 7 (depends on 6)

The composition of claim 6, wherein said solid PEG has an average molecular weight ranging between 1000 and 10000.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said average molecular weight ranges between 3350 and 8000.

### Claim 9 (depends on 8)

The composition of claim 8, wherein said average molecular weight is 8000.

### Claim 10 (depends on 1)

The composition of claim 1, wherein said nonvolatile cosolvent is a liquid PEG.

### Claim 11 (depends on 10)

The composition of claim 10, wherein said liquid PEG has a molecular weight less than or equal to 800.

### Claim 12 (depends on 2)

The composition of claim 2 wherein said composition forms a pharmaceutically acceptable cake after lyophilization.

### Claim 13

A process of making a pharmaceutically acceptable cake comprising the steps of:
(a) forming a solution comprising a therapeutic compound, an aqueous solvent, a nonvolatile cosolvent and a bulking agent, said solution being free of a volatile solvent; and
(b) lyophilizing said solution to form a pharmaceutically acceptable cake.

### Claim 14 (depends on 13)

The process of claim 13, wherein said bulking agent is a solid PEG.

### Claim 15 (depends on 14)

The process of claim 14, wherein said solid PEG has an average molecular weight ranging between 1000 and 10000.

### Claim 16 (depends on 15)

The process of claim 15, wherein said average molecular weight ranges between 3350 and 8000.

### Claim 17 (depends on 15)

The process of claim 15, wherein said average molecular weight is 8000.

### Claim 18 (depends on 13)

The process of claim 13, wherein said nonvolatile cosolvent is a liquid PEG.

### Claim 19 (depends on 13)

The process of claim 13, wherein said liquid PEG has an average molecular weight less than or equal to 800.

### Claim 20 (depends on 13)

The process of claim 13, wherein said solution further comprises a surfactant.

### Claim 21 (depends on 13)

The pharmaceutically acceptable cake produced by the process of claim 13.

### Claim 22

A pharmaceutically acceptable cake comprising:
(a) a poorly water-soluble therapeutic compound;
(b) a nonvolatile cosolvent, said nonvolatile cosolvent comprising from about 5% to about 80% by weight of the cake; and
(c) a bulking agent, said bulking agent comprising from about 10% to about 80% % by weight of the cake.

### Claim 23 (depends on 22)

The pharmaceutically acceptable cake of claim 22, wherein said nonvolatile cosolvent is a liquid PEG.

### Claim 24 (depends on 23)

The pharmaceutically acceptable cake of claim 23, wherein said bulking agent is a solid PEG.
